WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXi Biologics (WXXWY) has launched WuXia293Stable, an innovative HEK293 cell line platform designed for developing and manufacturing difficult-to-express molecules. The platform achieves fed-batch titers up to 5.0 g/L for monoclonal antibodies while significantly improving purity.
The new platform demonstrates high titers, human glycosylation, and improved product quality by reducing truncation issues common in complex modalities. WuXia293Stable maintains stable expression during long-term cell passages and offers scalable manufacturing capabilities at 2000L scale for fed-batch and 1000L scale for perfusion.
This addition strengthens WuXi Biologics' WuXia鈩� platform family, which includes other specialized platforms like WuXiaADCC Plus鈩� and WuXia RidGS鈩�, enhancing the company's comprehensive biologics development capabilities.
WuXi Biologics (WXXWY) ha lanciato WuXia293Stable, una piattaforma innovativa basata su cellule HEK293 progettata per lo sviluppo e la produzione di molecole difficili da esprimere. La piattaforma raggiunge titoli in fed-batch fino a 5,0 g/L per anticorpi monoclonali, migliorando in modo significativo la purezza.
La nuova piattaforma mostra elevati titoli, glicosilazione di tipo umano e una qualit脿 del prodotto superiore grazie alla riduzione dei problemi di troncamento comuni nelle modalit脿 complesse. WuXia293Stable mantiene un'espressione stabile durante passaggi cellulari prolungati e offre capacit脿 di produzione scalabili a 2000 L in fed-batch e 1000 L in perfusione.
Questa aggiunta rafforza la famiglia di piattaforme WuXia鈩� di WuXi Biologics, che include altre soluzioni specializzate come WuXiaADCC Plus鈩� e WuXia RidGS鈩�, potenziando le capacit脿 complessive dell'azienda nello sviluppo di biologici.
WuXi Biologics (WXXWY) ha lanzado WuXia293Stable, una innovadora plataforma de c茅lulas HEK293 dise帽ada para desarrollar y fabricar mol茅culas dif铆ciles de expresar. La plataforma alcanza t铆tulos en fed-batch de hasta 5,0 g/L para anticuerpos monoclonales, mejorando significativamente la pureza.
La nueva plataforma ofrece altos t铆tulos, glic贸silaci贸n humana y una mayor calidad del producto al reducir los problemas de truncamiento habituales en modalidades complejas. WuXia293Stable mantiene una expresi贸n estable durante pasajes celulares a largo plazo y proporciona capacidades de fabricaci贸n escalables a 2000 L en fed-batch y 1000 L en perfusi贸n.
Esta incorporaci贸n fortalece la familia de plataformas WuXia鈩� de WuXi Biologics, que incluye otras plataformas especializadas como WuXiaADCC Plus鈩� y WuXia RidGS鈩�, ampliando las capacidades integrales de desarrollo de productos biol贸gicos de la compa帽铆a.
WuXi Biologics (WXXWY)臧赌 WuXia293Stable鞚� 於滌嫓頄堨姷雼堧嫟. 鞚措姅 氚滍槃鞚� 鞏措牑鞖� 攵勳瀽霌れ潣 臧滊皽 氚� 鞝滌“毳� 鞙勴暣 靹り硠霅� 順侅嫚鞝侅澑 HEK293 靹疙彫欤� 頂岆灚韽检瀰雼堧嫟. 頃措嫻 頂岆灚韽检潃 雼伌搿犿暛觳挫棎 雽�頃� fed-batch 韮�鞚错劙 斓滊寑 5.0 g/L毳� 雼劚頃橂┐靹� 靾滊弰毳� 韥矊 頄レ儊鞁滌及鞀惦媹雼�.
靸� 頂岆灚韽检潃 雴掛潃 韮�鞚错劙, 鞚戈皠順� 雼鬼檾 氚� 氤奠灐頃� 鞝滍槙鞐愳劀 頋旐瀳 氚滌儩頃橂姅 鞝堧嫧(truncation) 氍胳牅鞚� 臧愳唽毳� 韱淀暣 頄レ儊霅� 鞝滍拡 頀堨鞚� 氤挫棳欷嶋媹雼�. WuXia293Stable鞚� 鞛リ赴 靹疙彫 瓿勲寑 氚办枒 霃欖晥 鞎堨爼鞝侅澑 氚滍槃鞚� 鞙犾頃橂┌ fed-batch 2000L 氚� 韻柬摠鞝� 1000L 攴滊搿� 頇曥灔 臧赌電ロ暅 鞝滌“ 鞐焿鞚� 鞝滉车頃╇媹雼�.
鞚措矆 於旉岸碾 WuXi Biologics鞚� WuXia鈩� 頂岆灚韽缄蛋鞚� 臧曧檾霅橃棃鞙茧┌, WuXiaADCC Plus鈩� 氚� WuXia RidGS鈩㈧檧 臧欖潃 雼るジ 韸鬼檾 頂岆灚韽茧摛瓿� 頃粯 須岇偓鞚� 鞝勲皹鞝侅澑 氚旍澊鞓れ潣鞎巾拡 臧滊皽 鞐焿鞚� 頄レ儊鞁滍偟雼堧嫟.
WuXi Biologics (WXXWY) a lanc茅 WuXia293Stable, une plateforme innovante de lign茅es cellulaires HEK293 con莽ue pour le d茅veloppement et la fabrication de mol茅cules difficiles 脿 exprimer. La plateforme atteint des titres en fed-batch allant jusqu'脿 5,0 g/L pour les anticorps monoclonaux tout en am茅liorant significativement la puret茅.
La nouvelle plateforme offre des titres 茅lev茅s, une glycosylation humaine et une meilleure qualit茅 de produit en r茅duisant les probl猫mes de troncature fr茅quents dans les modalit茅s complexes. WuXia293Stable maintient une expression stable lors de passages cellulaires 脿 long terme et propose des capacit茅s de fabrication 茅volutives 脿 2000 L en fed-batch et 1000 L en perfusion.
Cette addition renforce la famille de plateformes WuXia鈩� de WuXi Biologics, qui comprend d'autres plateformes sp茅cialis茅es telles que WuXiaADCC Plus鈩� et WuXia RidGS鈩�, renfor莽ant les capacit茅s globales de l'entreprise en d茅veloppement de biologiques.
WuXi Biologics (WXXWY) hat WuXia293Stable eingef眉hrt, eine innovative HEK293-Zelllinienplattform zur Entwicklung und Herstellung von schwer exprimierbaren Molek眉len. Die Plattform erzielt Fed-Batch-Titer von bis zu 5,0 g/L f眉r monoklonale Antik枚rper und verbessert dabei die Reinheit deutlich.
Die neue Plattform zeigt hohe Titer, menschliche Glykosylierung und verbesserte Produktqualit盲t durch Verringerung von Trunkierungsproblemen, die bei komplexen Modalit盲ten h盲ufig auftreten. WuXia293Stable beh盲lt eine stabile Expression 眉ber langfristige Zellpassagen bei und bietet skalierbare Herstellungsf盲higkeiten auf 2000 L f眉r Fed-Batch und 1000 L f眉r Perfusion.
Diese Erg盲nzung st盲rkt die WuXia鈩�-Plattformfamilie von WuXi Biologics, zu der auch spezialisierte Plattformen wie WuXiaADCC Plus鈩� und WuXia RidGS鈩� geh枚ren, und erweitert die umfassenden Entwicklungskapazit盲ten des Unternehmens im Bereich Biologika.
- Achieves high fed-batch titer of up to 5.0 g/L for monoclonal antibodies
- Platform eliminates or significantly reduces truncation issues in complex molecules
- Offers scalable manufacturing capabilities up to 2000L for fed-batch and 1000L for perfusion
- Maintains stable expression and consistent product quality during long-term cell passages
- None.
- WuXia293Stable聽platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules.
- WuXia293Stable聽platform maintains stable expression and consistent product quality during long-term cell passages, enabling scalable clinical and commercial manufacturing.
Conventionally, CHO cells have been widely utilized for recombinant protein expression with proven track record of high titers, and good developability and manufacturability. However, complex modalities may not be compatible with CHO expression system, resulting in low titer levels and truncation issues, due to the impact of some CHO-specific host cell proteins (HCPs), that compromise the quality and functionality of the protein products. In contrast, HEK293 cells can eliminate or significantly alleviate truncation issues in expressing complex molecules while maintaining high titer levels.
WuXi Biologics developed WuXia293Stable by leveraging its proprietary HEK293 cell line. Derived from WuXi Biologics' highly-vetted mammalian cell line development platform family WuXia鈩�, WuXia293Stable demonstrates productivity, quality and stability comparable to WuXia鈩� while maintaining full compatibility with its process, as shown by its robust growth and balanced metabolism.
The platform achieves a fed-batch titer of up to 5.0 g/L for monoclonal antibodies while significantly improving purity. WuXia293Stable offers flexible scalability in culture scale to meet the diverse needs of various research and pre-clinical development stages. Furthermore, the WuXia293Stable cell line maintains stable expression and consistent quality during long-term cell passages, enabling scalable clinical and commercial manufacturing at 2000L scale for fed-batch and 1000L scale for perfusion. Moreover, WuXi Biologics offers a comprehensive suite of services for the WuXia293Stable platform, including cell bank testing and viral clearance validation as part of its one-stop CMC solution.
The launch of the WuXia293Stable聽platform has further strengthened the service capabilities of WuXi Biologics' WuXia鈩� platform family. Besides WuXia293stable, the WuXia鈩� platform has already derived multiple cell line development platforms, including WuXiaADCC Plus鈩� and WuXia RidGS鈩�, to address customers' diverse requirements.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are excited to launch an industry-leading solution that significantly enhances the development of advanced therapeutics. WuXia293Stable stands as a powerful testament to WuXi Biologics' unwavering commitment to our vision that every biologic can be made and exemplifies our dedication to technological innovation, which enables us to adeptly address the evolving needs of the biopharmaceutical industry. Once again we are reaffirming our promise to enable our clients in accelerating the delivery of innovative biologics to patients worldwide. "
About the WuXia鈩⒙燙ell Line Development Platform Family
WuXia鈩� is a proven, high-yield (up to about 11 g/L) mammalian cell line platform family developed by WuXi Biologics. Accepted by regulatory agencies worldwide, the WuXia鈩� platform family have generated over 1000 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing as of 2024.
The WuXia鈩� platform family include WuXiaADCC聽Plus鈩� for developing and manufacturing afucosylated antibodies to elicit an enhanced ADCC response, WuXia RidGS鈩⒙爁or non-antibiotic cell line development, and the latest WuXia293Stable for expressing difficult-to-express molecules built on HEK293 cell lines. The WuXia鈩� cell line development platform family continue to expand to cater to the diverse needs of global customers.
View original content:
SOURCE WuXi Biologics
FAQ
What is WuXi Biologics' new WuXia293Stable platform and what does it do?
How does WuXia293Stable compare to traditional CHO cell expression systems?
What manufacturing scale can WuXi Biologics' WuXia293Stable platform achieve?
What services does WuXi Biologics offer with the WuXia293Stable platform?
What are the key advantages of WXXWY's WuXia293Stable platform for biologics development?
